{"id":11327,"date":"2025-07-27T00:27:33","date_gmt":"2025-07-26T22:27:33","guid":{"rendered":"https:\/\/valintermed.com\/?p=11327"},"modified":"2025-07-27T00:27:33","modified_gmt":"2025-07-26T22:27:33","slug":"gangliozidoz-gm1","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/gangliozidoz-gm1\/","title":{"rendered":"GM1 gangliosidosis"},"content":{"rendered":"
<\/div>\n

GM1 gangliosidosis (or GM1 disease) is a rare genetic disorder of metabolism caused by a deficiency of the enzyme \u03b2-galactosidase. This results in the accumulation of gangliosides, which are complex lipids, in the body's cells, particularly in the nervous system. The disease is characterized by significant neurological pathology beginning in early childhood and can manifest as progressive symptoms including developmental delay, hypotonia, ataxic movements, and cognitive impairment. As the disease progresses, toxic substances accumulate, leading to the destruction of nerve cells and their functional impairment, which ultimately affects the patient's life.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n